Both in Pharmaceuticals
Aclaris Therapeutics vs Climb Bio
Over the past year ACRS returned +46.1% and CLYM returned +387.5%; their daily moves had a correlation of 0.22.
ACRS +46.1% CLYM +387.5%Growth of $1, one year, split-adjusted
| Metric | ACRS | CLYM |
|---|---|---|
| Price | $3.74 | $9.75 |
| Market cap | $579.6M | $560.0M |
| Today | −1.58% | +0.10% |
| 1 month | −12.4% | −11.8% |
| 6 months | −21.3% | −14.8% |
| Year to date | +24.3% | +143.8% |
| 1 year | +48.4% | +375.6% |
| Revenue growth (YoY) | −8.3% | — |
| Gross margin | 86.6% | — |
| Net margin | −1320.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 70.5× | — |
| Net cash | $91.6M | $183.1M |
| Dividend yield | — | — |
| Volatility (60d) | 75.8% | 80.7% |
| Short % of float | 12.4% | 25.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).